Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition

Now in its twelfth edition — Worldwide Market for Point-of-Care (POC) Diagnostic Tests analyzes the POC market from a global perspective with a five-year forecast.

Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition provides a comprehensive analysis of the global POC diagnostics market, with forecasts extending through 2029. While traditional lab-based analyzers remain central to the in vitro diagnostics (IVD) industry, the POC segment has emerged as a dynamic growth area, driven by the demand for rapid, accessible testing across diverse healthcare settings.

This twelfth edition builds on Kalorama Information’s two decades of expertise in tracking POC trends, offering detailed insights into the evolving role of diagnostics in enhancing patient care, supporting clinical decision-making, and enabling decentralized testing—from hospitals to homes. The report highlights how technological innovations such as smartphones, biosensors, lab-on-a-chip platforms, and wearable devices are reshaping the POC landscape.

The study features in-depth segmentation across key test categories—including glucose, cardiac markers, infectious diseases, and critical care—and provides market sizing, growth projections, and competitive analysis. It also examines the diverse venues where POC testing is performed, from emergency departments and retail clinics to nursing homes and self-testing environments.

Enhanced Segmentation - Many Reports in One

The report delves into various areas of POC diagnostics, including:

• Blood and Electrolytes (including Blood Gases/Electrolytes, Hemoglobin/Hematocrit, WBC)
• Cancer Tumor Markers
• Cardiac Markers
• Coagulation
• Colon Cancer
• Drugs of Abuse
• Fecal Occult Blood
• Glucose (including CGM and Diabetes/HbA1c)
• Infectious Disease (including C. Diff, COVID-19, E. coli, H. pylori, Hepatitis, HIV, Home Test/OTC, Influenza, Malaria, STD, Others)
• Lipid
• Pregnancy/Fertility
• Urine
• Other Testing (including allergy, autoimmune, microbiology, TSH)

Each area is thoroughly analyzed, providing market sizing and forecasts.

Scope and Methodology

With global coverage spanning the U.S., Europe, Japan, and emerging markets, the report offers regional breakdowns and insights into regulatory trends, such as the pursuit of CLIA waivers and CE Marks. Data is based on extensive primary and secondary research, including interviews with over 35 industry stakeholders. Market estimates reflect manufacturer-level revenues, with forecasts from 2024 to 2029 and compound annual growth rates (CAGRs) for each segment.